Nektar Therapeutics

Other

Inq Biosciences Corporation

Aaron S Hammons

Jennifer A Riggs-Sauthier

Franco J Duarte

Timothy A Riley

Zhongxu Ren

Laurie A VanderVeen

Joseph Ralph McGinty

Steven Michael Faes

David Langford

Micah Brandon Harvey

Christopher David Pittman

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.

Oligomer-beta blocker conjugates

The invention provides water-soluble oligomer-beta blocker drug conjugates. A drug conjugate of the invention can be administered by any of a number of administration routes and exhibits properties that are different from the corresponding beta blocker not attached to the water-soluble oligomer.

Culture systems, devices and related methods and articles may automate the culturing or incubation process according to defined culturing protocols. Such may employ removable multi-well growth cassette. Wells may be subdivided into subwells. Such may employ removable media and waste cartridges and/or gas canisters to supply consumables, which may be supplied in kits, for example with processor executable culturing protocols. Direct fluidic coupling between growth cassettes and the removable cartridges or canisters may be employed. Operational and/or environmental conditions may be sensed or monitored, and may be used to adjust or alter operation. A microscopy subsystem may capture images which may be stored and/or analyzed. Analysis may be used to adjust or alter operation.

Culture systems, apparatus, and related methods and articles

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages over previously administered compounds.

Oligomer-nucleoside phosphate conjugates

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.

Growing community of inventors

Huntsville, AL, United States of America

Aaron S Hammons